Institutional members access full text with Ovid®

Treatment of AIDS-related lymphomas: rituximab is beneficial even in severely immunosuppressed patients

Wyen, Christopha; Jensen, Björnb; Hentrich, Marcusc; Siehl, Jand; Sabranski, Michaele; Esser, Stefanf; Gillor, Daniela; Müller, Markusg; Van Lunzen, Janh; Wolf, Timoi; Bogner, Johannes R.j; Wasmuth, Jan C.k; Christ, Hildegardl; Fätkenheuer, Gerda; Hoffmann, Christianm,n

doi: 10.1097/QAD.0b013e32834f30fa
Clinical Science

Objective: AIDS-related lymphomas (ARLs) significantly contribute to mortality in HIV-infected patients. Optimal chemotherapy treatment and the use of rituximab remain controversial. The aim of the present cohort study was to analyze the outcome of HIV-infected patients diagnosed with ARL, with regard to the use of rituximab, clinical characteristics and histopathological markers.

Methods and design: This observational uncontrolled multicenter cohort study included 163 HIV-infected patients with ARL diagnosed between January 2005 and December 2008 in Germany.

Results: Patients with CD20-positive ARL had a significantly better overall survival (OS) and progression-free survival (PFS) than patients with CD20-negative ARL [hazard ratio 0.28, 95% confidence interval (CI) 0.15–0.53 and hazard ratio 0.29, 95% CI 0.16–0.53]. In CD20-positive cases, the use of rituximab was associated with better OS and PFS (n = 128, hazard ratio 0.48, 95% CI 0.25–0.93 and hazard ratio 0.47, 95% CI 0.26–0.86), even in patients with severe immune deficiency at ARL diagnosis (CD4 T-cell count<100 cells/μl, n = 33; OS: hazard ratio 0.25, 95% CI 0.07–0.90). In multivariate analysis, CD4 T-cell counts more than 100 cells/μl and the use of rituximab were associated with better OS and PFS. In total, there were 12 polychemotherapy-associated deaths, which were not related to specific therapy regimens or to the use of rituximab.

Conclusion: In patients with CD20-positive ARL, CD4 T-cell count at ARL diagnosis and the use of rituximab had strong impact on survival. Rituximab was beneficial in ARL even in the setting of severe immune deficiency and was not associated with an increased risk of fatal infections.

aFirst Department of Internal Medicine, University of Cologne, Cologne

bDepartment of Gastroenterology, Hepatology and Infectiology, Düsseldorf University Hospital, Düsseldorf

cDepartment of Hematology and Oncology, Hospital Harlaching, Munich

dÄrzteforum Seestrasse, Berlin

eIFI Institute for Interdisciplinary Medicine, Hamburg

fDepartment of Dermatology, University of Essen, Essen

gDepartment of Internal Medicine, Vivantes Klinikum Neukölln, Berlin

hDepartment of Internal Medicine, University of Hamburg-Eppendorf, Hamburg

iDepartment of Internal Medicine, Hospital of the Johann Wolfgang Goethe-University, Frankfurt am Main

jDepartment of Internal Medicine, University of Munich, Munich

kDepartment of Internal Medicine I, University of Bonn, Bonn

lInstitute of Medical Statistics, Informatics and Epidemiology, University of Cologne, Cologne

mIPM Study Center, Hamburg

nUniversity of Schleswig-Holstein, Kiel, Germany.

Correspondence to Dr Christoph Wyen, MD, First Department of Internal Medicine, University Hospital of Cologne, Joseph Stelzmann Street 9, 50924 Cologne, Germany. Tel: +49 221 478 3324; fax: +49 221 478 5915; e-mail: christoph.wyen@uk-koeln.de

Received 12 August, 2011

Revised 2 November, 2011

Accepted 14 November, 2011

© 2012 Lippincott Williams & Wilkins, Inc.